Sorrento Therapeutics (LTS:0L85) EBITDA Margin %: -676.23% (As of Jun. 2023)


LTS:0L85 Sorrento Therapeutics Inc LTS:0L85
12 GF Score
Price $0.00
View Full Analysis

What is Sorrento Therapeutics EBITDA Margin %?

Sorrento Therapeutics LTS:0L85 12 EBITDA Margin % is -676.23% as of Jun. 2023. GuruFocus rates LTS:0L85 with a GF Score™ of 12/100.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Sorrento Therapeutics's EBITDA for the three months ended in Jun. 2023 was $-101.60 Mil. Sorrento Therapeutics's Revenue for the three months ended in Jun. 2023 was $15.03 Mil. Therefore, Sorrento Therapeutics's EBITDA margin for the quarter that ended in Jun. 2023 was -676.23%.

Sorrento Therapeutics  (LTS:0L85) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Sorrento Therapeutics EBITDA Margin % Related Terms

Sorrento Therapeutics EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Sorrento Therapeutics's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sorrento Therapeutics EBITDA Margin % Chart

Sorrento Therapeutics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -692.00 -997.52 -698.78 -831.40 -859.22

Sorrento Therapeutics Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1,876.35 -503.17 -1,314.14 -849.39 -676.23

LTS:0L85 vs IMUX, OCUP, KZR: EBITDA Margin % Comparison

For the Biotechnology subindustry, Sorrento Therapeutics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sorrento Therapeutics EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sorrento Therapeutics's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Sorrento Therapeutics's EBITDA Margin % falls into.


LTS:0L85
12GF Score
Sorrento Therapeutics Inc LTS:0L85
EBITDA Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sorrento Therapeutics EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Sorrento Therapeutics's EBITDA Margin % for the fiscal year that ended in Dec. 2022 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2022 )/Revenue (A: Dec. 2022 )
=-539.928/62.839
=-859.22 %

Sorrento Therapeutics's EBITDA Margin % for the quarter that ended in Jun. 2023 is calculated as

EBITDA Margin %=EBITDA (Q: Jun. 2023 )/Revenue (Q: Jun. 2023 )
=-101.604/15.025
=-676.23 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of -676.23% mean?
Sorrento Therapeutics (LTS:0L85) has a EBITDA Margin % of -676.23% as of Jun. 2023. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Sorrento Therapeutics and its competitors.
Is Sorrento Therapeutics' EBITDA Margin % too high?
Sorrento Therapeutics' current EBITDA Margin % is -676.23%. Overall, Sorrento Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Sorrento Therapeutics' EBITDA Margin % compare to IMUX and OCUP?
Sorrento Therapeutics' EBITDA Margin % of -676.23% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Sorrento Therapeutics and its competitors. Sorrento Therapeutics's current EBITDA Margin % is -676.23%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sorrento Therapeutics stock overvalued right now?
Sorrento Therapeutics (LTS:0L85) has a current EBITDA Margin % of -676.23%. The current EBITDA Margin % is -676.23%. Sorrento Therapeutics' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Sorrento Therapeutics (LTS:0L85), the current EBITDA Margin % is -676.23% as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sorrento Therapeutics Business Description

Address 4955 Directors Place, San Diego, CA, USA, 92121
Sorrento Therapeutics Inc is a clinical and commercial-stage biopharmaceutical company developing a portfolio of next-generation treatments for three major therapeutic areas: cancer, infectious disease, and pain. Its multimodal, multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as fully human antibodies (G-MAB library), immuno-cellular therapies (DAR-T), antibody-drug conjugates (ADCs), and oncolytic virus (Seprehvec). Sorrento is also developing potential antiviral therapies and vaccines against coronaviruses, including COVI-AMG, COVIDROPS, COVISHIELD, FUJOVEE (Abivertinib), and OQORY (Covi-MSC), and diagnostic test solutions, including COVITRACK and COVIMARK.
12GF Score

Get the complete analysis for LTS:0L85

EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price